JP2009518422A5 - - Google Patents

Download PDF

Info

Publication number
JP2009518422A5
JP2009518422A5 JP2008544468A JP2008544468A JP2009518422A5 JP 2009518422 A5 JP2009518422 A5 JP 2009518422A5 JP 2008544468 A JP2008544468 A JP 2008544468A JP 2008544468 A JP2008544468 A JP 2008544468A JP 2009518422 A5 JP2009518422 A5 JP 2009518422A5
Authority
JP
Japan
Prior art keywords
myostatin
pharmaceutical composition
binding
composition according
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008544468A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009518422A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/046546 external-priority patent/WO2007067616A2/en
Publication of JP2009518422A publication Critical patent/JP2009518422A/ja
Publication of JP2009518422A5 publication Critical patent/JP2009518422A5/ja
Pending legal-status Critical Current

Links

JP2008544468A 2005-12-06 2006-12-06 ミオスタチン・アンタゴニストの使用 Pending JP2009518422A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74273105P 2005-12-06 2005-12-06
PCT/US2006/046546 WO2007067616A2 (en) 2005-12-06 2006-12-06 Uses of myostatin antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012200485A Division JP2013028620A (ja) 2005-12-06 2012-09-12 ミオスタチン・アンタゴニストの使用

Publications (2)

Publication Number Publication Date
JP2009518422A JP2009518422A (ja) 2009-05-07
JP2009518422A5 true JP2009518422A5 (https=) 2010-07-08

Family

ID=38123451

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2008544468A Pending JP2009518422A (ja) 2005-12-06 2006-12-06 ミオスタチン・アンタゴニストの使用
JP2012200485A Pending JP2013028620A (ja) 2005-12-06 2012-09-12 ミオスタチン・アンタゴニストの使用
JP2014111126A Pending JP2014224115A (ja) 2005-12-06 2014-05-29 ミオスタチン・アンタゴニストの使用
JP2015235158A Pending JP2016094427A (ja) 2005-12-06 2015-12-01 ミオスタチン・アンタゴニストの使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2012200485A Pending JP2013028620A (ja) 2005-12-06 2012-09-12 ミオスタチン・アンタゴニストの使用
JP2014111126A Pending JP2014224115A (ja) 2005-12-06 2014-05-29 ミオスタチン・アンタゴニストの使用
JP2015235158A Pending JP2016094427A (ja) 2005-12-06 2015-12-01 ミオスタチン・アンタゴニストの使用

Country Status (7)

Country Link
US (3) US20070149458A1 (https=)
EP (1) EP1968621A2 (https=)
JP (4) JP2009518422A (https=)
AU (3) AU2006321906C1 (https=)
CA (2) CA2632544C (https=)
MX (1) MX2008007324A (https=)
WO (1) WO2007067616A2 (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1771470B1 (en) 2004-07-23 2013-06-26 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
BRPI0616923A2 (pt) * 2005-10-06 2011-07-05 Lilly Co Eli anticorpos monoclonais, seus usos e composição farmacêutica
UA92504C2 (en) * 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
KR20190006086A (ko) 2005-11-23 2019-01-16 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도
CA2661836A1 (en) * 2006-09-05 2008-03-13 Eli Lilly And Company Anti-myostatin antibodies
DK2124999T3 (da) 2006-12-18 2013-01-14 Acceleron Pharma Inc Activin-actrii antagonister og anvendelser til behandling af anæmi
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
EP2111229B1 (en) 2007-02-01 2013-04-10 Acceleron Pharma, Inc. Pharmaceutical compositions comprising Activin-ActRIIA antagonists for use in preventing or treating breast cancer metastasis or breast cancer related bone loss
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
ES2756725T3 (es) 2007-02-09 2020-04-27 Acceleron Pharma Inc Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIA
EP3243524A1 (en) 2007-09-18 2017-11-15 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
AU2009262970A1 (en) 2008-06-26 2009-12-30 Acceleron Pharma Inc. Methods for dosing an activin-ActRIIa antagonist and monitoring of treated patients
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
SMT202300222T1 (it) 2008-08-14 2023-09-06 Acceleron Pharma Inc Trappole di gdf
US8138142B2 (en) 2009-01-13 2012-03-20 Acceleron Pharma Inc. Methods for increasing adiponectin in a patient in need thereof
JP5766179B2 (ja) 2009-04-27 2015-08-19 ノバルティス アーゲー 筋肉増殖を増加させるための組成物および方法
BRPI1010587A2 (pt) 2009-06-08 2019-04-09 Acceleron Pharma Inc. métodos para aumentar adipócitos termogênicos
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
JP6267425B2 (ja) 2009-11-17 2018-01-24 アクセルロン ファーマ， インコーポレイテッド 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
UY33421A (es) 2010-06-03 2011-12-30 Glaxo Wellcome House Proteinas de union al antígeno humanizados
US8999343B2 (en) 2010-08-16 2015-04-07 Amgen Inc. Antibodies that bind myostatin, compositions and methods
CN103298832A (zh) 2010-11-08 2013-09-11 阿塞勒隆制药公司 Actriia结合剂及其用途
WO2012151718A1 (zh) * 2011-05-11 2012-11-15 湖北省农业科学院畜牧兽医研究所 猪肌抑素基因启动子及其应用
AU2012339722B2 (en) 2011-11-14 2017-09-14 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and/or Activin A
WO2013137832A1 (en) * 2012-03-16 2013-09-19 Nanyang Technological University Myostatin inhibitors
TWI633117B (zh) 2012-09-13 2018-08-21 必治妥美雅史谷比公司 結合至肌肉生長抑制素（ｍｙｏｓｔａｔｉｎ）以纖維連接蛋白爲主之支架結構域蛋白質
NZ707477A (en) 2012-11-02 2019-09-27 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders
US20160038588A1 (en) * 2013-03-15 2016-02-11 Amgen Inc. Myostatin Antagonism in Human Subjects
WO2014189475A1 (en) * 2013-05-24 2014-11-27 Alkoçlar Erdal Can A composition for treating the muscle weakness and the loss of muscle mass following chronic stroke and coma
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
WO2015134535A1 (en) * 2014-03-03 2015-09-11 Pinta Biotherapeutics, Inc. Combination therapy
WO2015187733A2 (en) * 2014-06-02 2015-12-10 Pinta Biotherapeutics, Inc. Myostatin inhibitors for treatment of diabetes
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
US10023621B2 (en) * 2014-06-04 2018-07-17 Acceleron Pharma Inc. Follistatin-related fusion proteins
WO2015192111A1 (en) 2014-06-13 2015-12-17 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
MX2017007519A (es) * 2014-12-08 2017-08-22 Novartis Ag Antagonistas de miostatina o activina para el tratamiento de sarcopenia.
AU2016238254B2 (en) * 2015-03-26 2022-05-05 Acceleron Pharma Inc. Follistatin-related fusion proteins and uses thereof
WO2016168613A1 (en) 2015-04-15 2016-10-20 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
WO2017031324A1 (en) * 2015-08-18 2017-02-23 Massachusetts Institute Of Technology Microfluidic platform for rapid biologics analysis
IL258574B2 (en) * 2015-11-11 2025-01-01 Novartis Ag Uses of myostatin antagonists, combinations containing them and their uses
JP6987072B2 (ja) 2016-03-10 2021-12-22 アクセレロン ファーマ インコーポレーテッド アクチビン２型受容体結合タンパク質及びその使用
TWI897843B (zh) 2017-05-03 2025-09-21 美商必治妥美雅史谷比公司 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物
WO2018218273A1 (en) * 2017-05-29 2018-12-06 Paranta Biosciences Limited Method of treating hypertension and kidney disease
CN111787981B (zh) 2018-03-01 2025-12-30 瑞泽恩制药公司 增加肌肉量和减少脂肪量的方法
WO2025177263A1 (en) 2024-02-25 2025-08-28 Biohaven Therapeutics Ltd. Myostatin-binding proteins
WO2025219859A1 (en) 2024-04-14 2025-10-23 Biohaven Therapeutics Ltd. Combination therapy to treat overweight, obesity, and related health conditions

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5750375A (en) * 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
DK0690873T3 (da) * 1993-03-19 2003-09-29 Univ Johns Hopkins Med Vækstdifferentieringsfaktor-8
US5994618A (en) * 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US6465239B1 (en) * 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
US6607884B1 (en) * 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6369201B1 (en) * 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
ES2330062T3 (es) * 1998-05-06 2009-12-03 Metamorphix, Inc. Procedimientos para tratar la diabetes por inhibicion de gdf-8.
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6284882B1 (en) * 1999-06-10 2001-09-04 Abbott Laboratories Myostatin gene promoter and inhibition of activation thereof
US7368534B2 (en) * 2000-01-18 2008-05-06 Orico Limited Myostatin and mimetics thereof
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
AR047392A1 (es) * 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
CN101287484B (zh) * 2002-12-20 2012-10-10 安姆根有限公司 抑制肌肉生长抑制素的结合剂
BRPI0410927A (pt) * 2003-06-02 2006-06-27 Wyeth Corp métodos terapêuticos e profiláticos para distúrbios neuromusculares
JP2007507429A (ja) * 2003-10-06 2007-03-29 モナシュ ユニバーシティー 治療方法
ATE555133T1 (de) * 2003-11-13 2012-05-15 Hanmi Holdings Co Ltd Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung
US8110665B2 (en) * 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
EP1729793B1 (en) * 2004-03-02 2015-07-22 Acceleron Pharma Inc. Alk7 and myostatin inhibitors for muscle wasting disorders
ATE557042T1 (de) * 2004-03-23 2012-05-15 Lilly Co Eli Anti-myostatin-antikörper
EA011879B1 (ru) * 2004-09-24 2009-06-30 Эмджин Инк. МОЛЕКУЛЫ С МОДИФИЦИРОВАННЫМ Fc ФРАГМЕНТОМ
KR100754667B1 (ko) * 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물

Similar Documents

Publication Publication Date Title
JP2009518422A5 (https=)
AU2019289200B2 (en) Bicyclic peptide ligands specific for Nectin-4
JP2012526729A5 (https=)
CN101815724B (zh) 用于将轭合至其的试剂递送至组织的抑肽酶样多肽
ES2548238T3 (es) Formulaciones antagonistas de VEGF
JP2014524908A5 (https=)
JP2017527272A5 (https=)
JP2016065060A5 (https=)
EP3665194A1 (en) Affinity-based methods for using transferrin receptor-binding proteins
CN102388062A (zh) 用于治疗癌症的trail变体
JP2010529957A5 (https=)
CN112533937A (zh) 用于结合cd38的肽配体
JP2016539096A5 (https=)
Zhao et al. Profound spinal tolerance after repeated exposure to a highly selective μ-opioid peptide agonist: role of δ-opioid receptors
JP2014525901A5 (https=)
KR20190071758A (ko) 신규한 하이브리드 actriib 리간드 트랩 단백질을 사용한 근육 소모 및 골 질환의 치료 방법
JP2014523884A5 (https=)
JP2020517658A5 (https=)
KR20190032427A (ko) 암 치료 조성물 및 방법
JP2018538356A5 (https=)
JP2019519529A5 (https=)
JP2010538005A5 (https=)
WO2019051164A1 (en) ANTIBODIES AGAINST PROTEIN 1 OF PROGRAMMED CELL DEATH
KR20190124247A (ko) Csf1r-기반 키메라 단백질
JP2010535486A5 (https=)